Antibody against uPA/uPAR

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07737256

ABSTRACT:
The invention herein disclosed relates to the anti-HIV action of uPAR-activators or activated uPAR molecules, the control of chemotaxis and cell migration by agents interfering with uPAR activation, a method for determining activated uPAR forms, the use of agents interfering with uPA/uPAR interaction for the diagnosis or therapy of diseases.

REFERENCES:
patent: 6077508 (2000-06-01), Rabbani et al.
patent: 6462170 (2002-10-01), Blasi et al.
patent: 0 691 350 (1996-01-01), None
patent: WO 90 12091 (1990-11-01), None
patent: WO 96 13160 (1996-05-01), None
patent: WO 01 38871 (2001-05-01), None
Andreasen Peter A. et al., “The urokinase-type plasminogen activator system in cancer metastasis: A review”, International Journal of Cancer, 1997, vol. 72, No. 1, pp. 1-22, XP-002210773.
Del Rosso M. et al., “The urokinase-type plasminogen activator system and inflammatory joint diseases”, Clinical and Experimental Rheumatology, Italy, 1999, vol. 17, No. 4, pp. 485-498, XP-001096329.
Fazioli Francesca et al., “A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity”, European Molecular Biology Organization Journal (EMBO), 1997, vol. 16, No. 24, pp. 7279-7286, XP-002072480.
Sidenius Nicolai et al., “Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection”, Blood, W.B. Saunders Company, Orlando, FL, US, 2000, vol. 96, No. 13, pp. 4091-4095, XP-002166383.
Sidenius Nicolai et al., “Shedding and cleavage of the urokinase receptor (uPAR); Identification and characterisation of uPAR fragments in vitro and in vivo”, FEBS Letters, 2000, vol. 475, No. 1, pp. 52-56, XP-004337232.
Slot Ole et al., “Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis”, Annals of the Rheumatic Diseases, 1999, vol. 58, No. 8, pp. 488-492, XP-001097411.
Wada Manabu et al., “Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication”, Biochemical and Biophysical Research Communications, Academic Press, San Diego, CA, US, 2001, vol. 284, No. 2, pp. 346-351, XP-002183644.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibody against uPA/uPAR does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibody against uPA/uPAR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody against uPA/uPAR will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4220045

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.